Western blot was performed to examine the knockdown efficiency and the results showed that both ADAR1 shRNAs (shA1 and shA2) could significantly reduce ADAR1 protein levels in all three ovarian cancer cell lines compared with non-targeted scramble shRNA (Fig. 2a). This evidence concerns the gene ADAR and ovarian carcinoma.